Key Takeaway
Buteyko breathing reduced beta-agonist inhaler use by 85% and inhaled steroid use by 50% over 6 months, with no adverse events and no change in lung function.
Summary
This single-blinded randomized controlled trial from New Zealand evaluated the Buteyko Breathing Technique in 38 asthma patients aged 18-70 over a 6-month follow-up period. The study found dramatic reductions in medication use without compromising safety.
The intervention group achieved an 85% reduction in beta-agonist use compared to 37% in controls, and a 50% reduction in inhaled steroids while controls showed no change. No adverse events were recorded in either group. Like other Buteyko trials, FEV1 did not change significantly, reinforcing that the technique reduces medication dependence and symptoms without altering objective airway function. The authors concluded Buteyko is a safe and effective asthma management approach with potential clinical and economic benefits.
Methods
- 38 adults with asthma aged 18-70 randomized to Buteyko or control
- Single-blinded design with equal investigator contact time for both groups
- 6-month follow-up period
- Measured beta-agonist use, inhaled steroid use, and FEV1
- Adverse events tracked throughout study period
Key Results
- 85% reduction in beta-agonist use in Buteyko group vs 37% in controls
- 50% reduction in inhaled steroid use in Buteyko group vs no change in controls
- No significant change in FEV1 in either group
- No adverse events recorded in either group
- Maintained asthma control despite large medication reductions
Limitations
- Small sample size (n=38)
- Single-blinded design (participants aware of group assignment)
- Single-center study in New Zealand
- Cannot determine which specific elements of Buteyko drive the effect